Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. ImmunityBio, Inc. is among the best biotech stocks. TheFly reported on January 20 that Piper Sandler raised its price target on IBRX to $7 from $5 and maintained an Overweight rating. According to the update, U.S. ANKTIVA net sales increased by almost 700% year over year to $113 million in 2025. Revenue is expected to reach $180 million in 2026. A possible label expansion for ANKTIVA in 2027 may be supported by positive QUILT- ...